Recurrent Pityriasis VersicolorNCT05067699
Vitamin D Level in Recurrent PV
An observational study of Recurrent Pityriasis Versicolor, run by Kasr El Aini Hospital at 1 site in Egypt.
Trial summary
Serum Samples will be taken from patients with recurrent Pityriasis Versicolor for the evaluation of vitamin D level. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Recurrent Pityriasis Versicolor
- What is being tested?
- Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)
- How many people
- 200 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2021to 1 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: Patients with recurrent Pityriasis Versicolor (more than 2 attacks per year) and of a disseminated nature
Who may be able to join
- - Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
- Patients of both genders.
- Age ≥18 years old.
Who cannot join
- - Patients with other cutaneous diseases.
- Patient's having dandruff (scaly scalp) even if not symptomatizing.
- Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
- Patients with autoimmune diseases.
- Patients with immunodeficiency diseases.
- Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Kasr Al Ainy Teaching Hospital
Cairo
Rana Hilal, M.d, 1001488869, rana.hilal@kasralainy.edu.eg
About this study
Official title: Serum Vitamin D Level Detection in Patients With Recurrent Pityriasis Versicolor
Serum Samples will be taken from patients with recurrent Pityriasis Versicolor for the evaluation of vitamin D level.
- Conditions
- Recurrent Pityriasis Versicolor
- Being tested
- Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)
- Medical subject headings
- Tinea Versicolor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)Diagnostic test
The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
| Study group | Role | What they receive |
|---|---|---|
| Patients | recurrent pityriasis versicolor Receives: Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well) | |
| Controls | Healthy age and sex matched Receives: Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum 25(OH) D3 level
The serum of patients and controls will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
Measured: 6months-1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2021
- Study start1 Sep 2021
- Primary completion1 Jan 2022 (estimated)
- Study completion1 Mar 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Recurrent Pityriasis VersicolorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kasr El Aini Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rana F Hilal, MD, Kasr El Aini Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05067699
- Sponsor's protocol ID
- VitD&PV
- Status last verified
- Sep 2021
- First submitted
- 24 Sep 2021
- Last updated
- 5 Oct 2021
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serum Vitamin D Level Detection in Patients With Recurrent Pityriasis Versicolor
- ClinicalTrials.gov ID
- NCT05067699
- Acronym / sponsor ID
- VitD&PV
- Conditions
- Recurrent Pityriasis Versicolor
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Kasr El Aini HospitalUniversity, hospital or other
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 1 Jan 2022 (estimated)
- Study completion
- 1 Mar 2022 (estimated)
- First posted
- 5 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Serum Samples will be taken from patients with recurrent Pityriasis Versicolor for the evaluation of vitamin D level.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients | – | Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)recurrent pityriasis versicolor |
| Controls | – | Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)Healthy age and sex matched |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Patients with recurrent Pityriasis Versicolor (more than 2 attacks per year) and of a disseminated nature
Key inclusion criteria (3 listed)
- - Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
- Patients of both genders.
- Age ≥18 years old.
Key exclusion criteria (6 listed)
- - Patients with other cutaneous diseases.
- Patient's having dandruff (scaly scalp) even if not symptomatizing.
- Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
- Patients with autoimmune diseases.
- Patients with immunodeficiency diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D). | Diagnostic test | Controls, Patients |
Primary outcome
Serum 25(OH) D3 level
Time frame: 6months-1 year
The serum of patients and controls will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2021.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Recurrent Pityriasis Versicolor, run by Kasr El Aini Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rana Hilal, M.D (+201001488869, rana.hilal@kasralainy.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum 25(OH) D3 level (time frame: 6months-1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2021.